Texas · J0881

Injection, Darbepoetin Alfa, 1 Microgram (non-Esrd Use) in Texas

Texas Medicare Avg
$2.34
0% above national avg
National Medicare Avg
$2.34
All states combined
Billed Charge (TX)
$18.54
What providers submit
Est. Commercial (TX)
$6.83
National avg: $6.64
Est. Cash / Self-Pay (TX)
$7.33
Typical self-pay discount

Estimated using RAND 2024 commercial-to-Medicare ratios. Actual prices vary by insurer, plan, and facility.

2.9M
Services in TX
496
Providers
N/A
Min Payment
N/A
Max Payment

Top Providers in Texas

Provider Medicare Services
Kocs, Darren MD $2.36 66.9K
Rieber, Alyssa M.D. $2.35 48.8K
Ulrich, Brian M.D. $2.34 48.7K
Rakkhit, Ronjay M.D. $2.36 47.2K
Patel, Ashvinkumar M.D. $2.23 43.6K
Nguyen, Alex M. D. $2.35 32.1K
Beeram, Sridhar MD $2.37 31.3K
Raizen, Yuval MD $2.35 30.8K
Arani, Mohsen MD $2.36 30.8K

Texas Pricing in Context

In Texas, CPT code J0881 (Injection, Darbepoetin Alfa, 1 Microgram (non-Esrd Use)) carries an average Medicare payment of $2.34 — 0% above the national benchmark of $2.34. 496 providers across the state submitted claims for this procedure in 2023, performing 2.9M total services. Individual payments in TX ranged from N/A at the low end to N/A at the high end, reflecting differences in provider setting (office vs. facility), modifiers, and the specific geographic locality code applied within the state.

The average billed charge in Texas is $18.54, which is the figure uninsured patients would most likely encounter before any negotiation or charity discount. Medicare, by statute, only reimburses the allowed amount — the balance between billed and paid is written off under provider participation agreements. Insured patients generally pay a negotiated rate that falls between these two figures; the exact amount depends on plan design, deductible status, and in-network participation. Because Texas sits above the national Medicare average, commercial rates in the state may also run higher than the US median.

Using RAND 2024 commercial-to-Medicare ratios for Drugs (Administered) procedures, the estimated commercial insurance price in Texas lands near $6.83, with self-pay cash prices typically around $7.33. Before scheduling, patients can request a Good Faith Estimate under the No Surprises Act, compare cash rates from hospital Machine-Readable Files, and confirm whether the provider is in-network with their specific plan. This page presents CMS reference data for informational use; it does not constitute medical or financial advice.

Frequently Asked Questions

How much does Injection, Darbepoetin Alfa, 1 Microgram (non-Esrd Use) cost in Texas?

The average Medicare payment for Injection, Darbepoetin Alfa, 1 Microgram (non-Esrd Use) in Texas is $2.34, which is 0% above the national average of $2.34. Providers in TX typically bill $18.54 for this procedure.

What does Injection, Darbepoetin Alfa, 1 Microgram (non-Esrd Use) cost with insurance in Texas?

With commercial insurance in Texas, Injection, Darbepoetin Alfa, 1 Microgram (non-Esrd Use) costs an estimated $6.83. Without insurance, the estimated cash price is $7.33. These estimates are based on RAND 2024 commercial-to-Medicare ratios and vary by insurer, plan, and facility.

How many providers perform Injection, Darbepoetin Alfa, 1 Microgram (non-Esrd Use) in Texas?

496 providers in Texas billed Medicare for Injection, Darbepoetin Alfa, 1 Microgram (non-Esrd Use) in 2023, performing 2.9M total services. Medicare payments ranged from N/A to N/A depending on the provider.

Is Injection, Darbepoetin Alfa, 1 Microgram (non-Esrd Use) cheaper in Texas than the national average?

No — Injection, Darbepoetin Alfa, 1 Microgram (non-Esrd Use) costs 0% above the national average in Texas. The state average Medicare payment is $2.34 compared to $2.34 nationally. Factors like local cost of living, provider competition, and regional Medicare fee schedules all influence state-level pricing.

Related

Data sourced from the CMS Medicare Physician and Other Practitioners dataset. See our methodology for details. Retrieved and formatted by PlainProcedure Editorial